Log In
Print
BCIQ
Print
Print this Print this
 

afacifenacin fumarate (NS-986, SMP-986)

  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionDual muscarinic receptor antagonist and sodium channel blocker
Molecular Target Muscarinic receptor ; Sodium channel
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation

Partner

Nippon Shinyaku Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today